204 related articles for article (PubMed ID: 37642226)
1. A Comprehensive Review on Current Treatments and Challenges Involved in the Treatment of Ovarian Cancer.
Saman S; Srivastava N; Yasir M; Chauhan I
Curr Cancer Drug Targets; 2024; 24(2):142-166. PubMed ID: 37642226
[TBL] [Abstract][Full Text] [Related]
2. Nanoscale drug delivery strategies for therapy of ovarian cancer: conventional vs targeted.
Gupta S; Pathak Y; Gupta MK; Vyas SP
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4066-4088. PubMed ID: 31625408
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery strategies to overcome multidrug resistance in ovarian cancer.
Khan IU; Khan RU; Asif H; Alamgeer ; Khalid SH; Asghar S; Saleem M; Shah KU; Shah SU; Rizvi SAA; Shahzad Y
Int J Pharm; 2017 Nov; 533(1):111-124. PubMed ID: 28947245
[TBL] [Abstract][Full Text] [Related]
4. Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.
Zhao MD; Li JQ; Chen FY; Dong W; Wen LJ; Fei WD; Zhang X; Yang PL; Zhang XM; Zheng CH
Int J Nanomedicine; 2019; 14():9453-9467. PubMed ID: 31819443
[TBL] [Abstract][Full Text] [Related]
5. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
6. Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article.
Khalifa AM; Elsheikh MA; Khalifa AM; Elnaggar YSR
J Control Release; 2019 Oct; 311-312():125-137. PubMed ID: 31476342
[TBL] [Abstract][Full Text] [Related]
7. Recent advances of polymeric nanoplatforms for cancer treatment: smart delivery systems (SDS), nanotheranostics and multidrug resistance (MDR) inhibition.
Gupta U; Maity D; Sharma VK
Biomed Mater; 2023 Nov; 19(1):. PubMed ID: 37944188
[TBL] [Abstract][Full Text] [Related]
8. Engineering extracellular vesicles mimetics for targeted chemotherapy of drug-resistant ovary cancer.
Liu X; Liu G; Mao Y; Luo J; Cao Y; Tan W; Li W; Yu H; Jia X; Li H
Nanomedicine (Lond); 2024 Jan; 19(1):25-41. PubMed ID: 38059464
[TBL] [Abstract][Full Text] [Related]
9. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
[TBL] [Abstract][Full Text] [Related]
10. Colloidal Nanocarriers as Versatile Targeted Delivery Systems for Cervical Cancer.
Sugumaran A; Mathialagan V
Curr Pharm Des; 2020; 26(40):5174-5187. PubMed ID: 32586249
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle-Based Combination Therapy for Ovarian Cancer.
Wu Y; Yang Y; Lv X; Gao M; Gong X; Yao Q; Liu Y
Int J Nanomedicine; 2023; 18():1965-1987. PubMed ID: 37077941
[TBL] [Abstract][Full Text] [Related]
12. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
Risnayanti C; Jang YS; Lee J; Ahn HJ
Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419
[TBL] [Abstract][Full Text] [Related]
13. Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.
J Vis Exp; 2023 May; (195):. PubMed ID: 37235796
[TBL] [Abstract][Full Text] [Related]
14. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
[TBL] [Abstract][Full Text] [Related]
15. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of Paclitaxel/Atovaquone/Quercetin to regulate energy metabolism to reverse multidrug resistance in ovarian cancer by PLGA-PEG nanoparticles.
Lu Q; Gao W; Chen Z; Liu Z; Wang J; Zeng L; Hu X; Zheng E; Zhang Q; Song H
Int J Pharm; 2024 Apr; 655():124028. PubMed ID: 38518871
[TBL] [Abstract][Full Text] [Related]
17. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
18. Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers.
McFadden M; Singh SK; Oprea-Ilies G; Singh R
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771642
[TBL] [Abstract][Full Text] [Related]
19. Multi-functional nanocarriers to overcome tumor drug resistance.
Jabr-Milane LS; van Vlerken LE; Yadav S; Amiji MM
Cancer Treat Rev; 2008 Nov; 34(7):592-602. PubMed ID: 18538481
[TBL] [Abstract][Full Text] [Related]
20. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
Gote V; Nookala AR; Bolla PK; Pal D
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
